Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer
Phase 3
- Conditions
- Ovarian Cancer
- Interventions
- Procedure: debulking surgery
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2022-05-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT05371301
- Locations
- 🇨🇳
Fudan university shanghai cancer center, Deparment of gynecologic oncology, Shanghai, Shanghai, China
A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis
Phase 2
Not yet recruiting
- Conditions
- Advanced Rectal CancerLiver MetastasisPulmonary MetastasisMicrosatellite Stable Colorectal Carcinoma
- Interventions
- Combination Product: a combination therapy including tislelizumab
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 52
- Registration Number
- NCT05359393
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 302
- Registration Number
- NCT05354674
- Locations
- 🇨🇳
Zhongshan hospital, Shanghai, Shanghai, China
Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo
Phase 2
- Conditions
- Advanced Malignant Tumors
- Interventions
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT05354076
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
HER2-positive Breast Cancer Project Initiated by Investigators
Phase 2
Not yet recruiting
- Conditions
- Breast Cancer
- Interventions
- Drug: Injection of A166
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 48
- Registration Number
- NCT05346328
Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab
Phase 3
Recruiting
- Conditions
- HER2-positive Breast CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 240
- Registration Number
- NCT05346861
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 42
- Registration Number
- NCT05316480
- Locations
- 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China
HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection
Phase 2
- Conditions
- Hepatocarcinoma
- Interventions
- Drug: HAIC+TQB2450+Anlotinib
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 70
- Registration Number
- NCT05311319
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Metformin and Insulin to Pancreatic Cancer Related Diabetes (Type 3c)
Phase 2
Active, not recruiting
- Conditions
- Pancretic CancerDiabete Mellitus
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 20
- Registration Number
- NCT05306028
- Locations
- 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China
Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients with Advanced Pancreatic Cancer
Phase 1
Completed
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 56
- Registration Number
- NCT05303090
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath